CA3234233A1 - Endonuclease systems - Google Patents
Endonuclease systems Download PDFInfo
- Publication number
- CA3234233A1 CA3234233A1 CA3234233A CA3234233A CA3234233A1 CA 3234233 A1 CA3234233 A1 CA 3234233A1 CA 3234233 A CA3234233 A CA 3234233A CA 3234233 A CA3234233 A CA 3234233A CA 3234233 A1 CA3234233 A1 CA 3234233A1
- Authority
- CA
- Canada
- Prior art keywords
- endonuclease
- sequence
- seq
- engineered
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163282999P | 2021-11-24 | 2021-11-24 | |
| US63/282,999 | 2021-11-24 | ||
| US202163289981P | 2021-12-15 | 2021-12-15 | |
| US63/289,981 | 2021-12-15 | ||
| US202263356908P | 2022-06-29 | 2022-06-29 | |
| US63/356,908 | 2022-06-29 | ||
| PCT/US2022/080437 WO2023097282A1 (en) | 2021-11-24 | 2022-11-23 | Endonuclease systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3234233A1 true CA3234233A1 (en) | 2023-06-01 |
Family
ID=86540394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3234233A Pending CA3234233A1 (en) | 2021-11-24 | 2022-11-23 | Endonuclease systems |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12410449B2 (enExample) |
| EP (1) | EP4437096A4 (enExample) |
| JP (1) | JP2024541402A (enExample) |
| KR (1) | KR20240110603A (enExample) |
| AU (1) | AU2022396533A1 (enExample) |
| CA (1) | CA3234233A1 (enExample) |
| MX (1) | MX2024006257A (enExample) |
| WO (1) | WO2023097282A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119452085A (zh) | 2021-08-27 | 2025-02-14 | 宏基因组学公司 | 具有ruvc结构域的酶 |
| KR20240110603A (ko) | 2021-11-24 | 2024-07-15 | 메타지노미, 인크. | 엔도뉴클레아제 시스템 |
| CN121241133A (zh) * | 2023-03-31 | 2025-12-30 | 阿伯生物技术公司 | Crispr核酸酶多肽和包含此类crispr核酸酶多肽的基因编辑系统 |
| WO2025117544A1 (en) * | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
| CN117384884B (zh) * | 2023-11-30 | 2024-03-08 | 辉大(上海)生物科技有限公司 | IscB多肽及其用途 |
| CN117511912B (zh) * | 2023-12-22 | 2024-03-29 | 辉大(上海)生物科技有限公司 | IscB多肽、包含其的系统及其用途 |
| WO2025207709A1 (en) * | 2024-03-26 | 2025-10-02 | Arbor Biotechnologies, Inc. | Reverse transcription-mediated gene editing systems and uses thereof |
| WO2026044118A1 (en) * | 2024-08-21 | 2026-02-26 | Metagenomi, Inc. | Endonuclease systems |
| WO2026073121A2 (en) * | 2024-09-30 | 2026-04-02 | Arbor Biotechnologies, Inc. | Compact gene editors for delivery by adeno-associated viral vectors |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| DK3363902T3 (da) | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| CN105209621B (zh) | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| US10584358B2 (en) | 2013-10-30 | 2020-03-10 | North Carolina State University | Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| EP3294342A4 (en) | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| MX2017014560A (es) | 2015-05-15 | 2018-03-01 | Pioneer Hi Bred Int | Caracterizacion rapida de sistemas de endonucleasa cas, secuencias pam y elementos arn de guia. |
| US10392607B2 (en) | 2015-06-03 | 2019-08-27 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
| US20160362667A1 (en) | 2015-06-10 | 2016-12-15 | Caribou Biosciences, Inc. | CRISPR-Cas Compositions and Methods |
| EP3929287A3 (en) | 2015-06-18 | 2022-04-13 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| EP3390632B1 (en) | 2015-12-18 | 2025-09-10 | Danisco US Inc. | Methods and compositions for polymerase ii (pol-ii) based guide rna expression |
| MX2018010484A (es) | 2016-03-04 | 2019-01-10 | Editas Medicine Inc | Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer. |
| EP3426780A1 (en) | 2016-03-11 | 2019-01-16 | Pioneer Hi-Bred International, Inc. | Novel cas9 systems and methods of use |
| WO2018035250A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
| CA3038982A1 (en) | 2016-09-30 | 2018-04-05 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| WO2018074979A1 (en) | 2016-10-17 | 2018-04-26 | Nanyang Technological University | Truncated crispr-cas proteins for dna targeting |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2018209712A1 (en) | 2017-05-19 | 2018-11-22 | Tsinghua University | Engineering of a minimal sacas9 crispr/cas system for gene editing and transcriptional regulation optimized by enhanced guide rna |
| CN110168078B (zh) | 2017-01-06 | 2024-05-14 | 免疫生物公司 | 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞 |
| MX2019011215A (es) | 2017-03-24 | 2020-02-12 | Curevac Ag | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. |
| CN110892069B (zh) | 2017-03-30 | 2024-02-09 | 国立大学法人京都大学 | 基于基因组编辑的外显子跳跃诱导方法 |
| BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| CN107164377A (zh) | 2017-06-12 | 2017-09-15 | 王小平 | 基于碱基编辑的基因敲除方法及其应用 |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US10253365B1 (en) | 2017-11-22 | 2019-04-09 | The Regents Of The University Of California | Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs |
| WO2019161290A1 (en) | 2018-02-15 | 2019-08-22 | Sigma-Aldrich Co. Llc | Engineered cas9 systems for eukaryotic genome modification |
| KR20200124702A (ko) | 2018-02-23 | 2020-11-03 | 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 | 신규한 cas9 오르소로그 |
| CA3093919A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| EP3775213A1 (en) | 2018-04-13 | 2021-02-17 | Sigma Aldrich Co. LLC | Modification of immune-related genomic loci using paired crispr nickase ribonucleoproteins |
| WO2020041120A1 (en) | 2018-08-20 | 2020-02-27 | Massachusetts Institute Of Technology | Robotic manipulation of objects using external contacts |
| WO2020055941A1 (en) * | 2018-09-13 | 2020-03-19 | Excision Biotherapeutics, Inc. | Compositions and methods for excision with single grna |
| CN110904045A (zh) | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| CA3116132A1 (en) | 2018-10-16 | 2020-04-23 | Intellia Therapeutics, Inc. | Compositions and methods for immunotherapy |
| KR20210116526A (ko) | 2019-01-16 | 2021-09-27 | 빔 테라퓨틱스, 인크. | 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포 |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| KR20240007322A (ko) | 2019-02-14 | 2024-01-16 | 메타지노미, 인크. | Ruvc 도메인이 존재하는 효소 |
| CN113728097A (zh) | 2019-02-14 | 2021-11-30 | 宏基因组学知识产权技术有限责任公司 | 具有ruvc结构域的酶 |
| US20220220460A1 (en) | 2019-02-14 | 2022-07-14 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| JP2020154564A (ja) | 2019-03-19 | 2020-09-24 | 富士通株式会社 | 学習方法、学習プログラムおよび学習装置 |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| US20220403357A1 (en) | 2019-11-12 | 2022-12-22 | The Broad Institute, Inc. | Small type ii cas proteins and methods of use thereof |
| CA3177051A1 (en) | 2020-03-31 | 2021-10-07 | Metagenomi, Inc. | Class ii, type ii crispr systems |
| WO2021202559A1 (en) * | 2020-03-31 | 2021-10-07 | Metagenomi Ip Technologies, Llc | Class ii, type ii crispr systems |
| CN116096892A (zh) | 2020-05-08 | 2023-05-09 | 宏基因组学公司 | 具有RuvC结构域的酶 |
| WO2021226369A1 (en) | 2020-05-08 | 2021-11-11 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| CA3192224A1 (en) | 2020-09-11 | 2022-03-17 | Jyun-Liang LIN | Base editing enzymes |
| CN112126661B (zh) | 2020-09-30 | 2022-07-22 | 上海中医药大学 | 一种高效敲除nk细胞中tigit基因的方法 |
| EP4203993A4 (en) | 2020-10-23 | 2024-10-23 | The Broad Institute, Inc. | Reprogrammable iscb nucleases and uses thereof |
| JP7877351B2 (ja) | 2021-03-19 | 2026-06-22 | メタゲノミ セラピューティクス，インク． | Ｃａｓ酵素を用いたマルチプレックス編集 |
| EP4330386A4 (en) | 2021-04-30 | 2025-05-14 | Metagenomi, Inc. | Enzymes with ruvc domains |
| KR20240110603A (ko) | 2021-11-24 | 2024-07-15 | 메타지노미, 인크. | 엔도뉴클레아제 시스템 |
| WO2023097262A1 (en) | 2021-11-24 | 2023-06-01 | Metagenomi, Inc. | Endonuclease systems |
-
2022
- 2022-11-23 KR KR1020247019181A patent/KR20240110603A/ko active Pending
- 2022-11-23 JP JP2024529294A patent/JP2024541402A/ja active Pending
- 2022-11-23 CA CA3234233A patent/CA3234233A1/en active Pending
- 2022-11-23 AU AU2022396533A patent/AU2022396533A1/en active Pending
- 2022-11-23 WO PCT/US2022/080437 patent/WO2023097282A1/en not_active Ceased
- 2022-11-23 MX MX2024006257A patent/MX2024006257A/es unknown
- 2022-11-23 EP EP22899556.9A patent/EP4437096A4/en active Pending
-
2024
- 2024-05-21 US US18/669,712 patent/US12410449B2/en active Active
-
2025
- 2025-07-29 US US19/284,314 patent/US20260078412A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12410449B2 (en) | 2025-09-09 |
| JP2024541402A (ja) | 2024-11-08 |
| EP4437096A1 (en) | 2024-10-02 |
| EP4437096A4 (en) | 2025-09-24 |
| AU2022396533A1 (en) | 2024-05-02 |
| US20260078412A1 (en) | 2026-03-19 |
| US20240294948A1 (en) | 2024-09-05 |
| WO2023097282A1 (en) | 2023-06-01 |
| KR20240110603A (ko) | 2024-07-15 |
| MX2024006257A (es) | 2024-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11946039B2 (en) | Class II, type II CRISPR systems | |
| US12410449B2 (en) | Endonuclease systems | |
| US20240117330A1 (en) | Enzymes with ruvc domains | |
| US12024727B2 (en) | Enzymes with RuvC domains | |
| US20240309404A1 (en) | Base editing enzymes | |
| WO2021202559A1 (en) | Class ii, type ii crispr systems | |
| US20240409962A1 (en) | Endonuclease systems | |
| US20240110167A1 (en) | Enzymes with ruvc domains | |
| CN118265783A (zh) | 核酸内切酶系统 | |
| US20240352433A1 (en) | Enzymes with hepn domains | |
| HK40084708B (en) | Class ii, type ii crispr systems | |
| HK40084708A (en) | Class ii, type ii crispr systems | |
| GB2594339A (en) | Enzymes with RUVC Domains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240918 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241112 |
|
| R15 | Change to inventor requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R15-R108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUEST RECEIVED Effective date: 20250805 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251111 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251111 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20260212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260216 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260218 |
|
| R16 | Change to inventor recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R16-R110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260304 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260304 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260304 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20260311 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260514 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260706 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260706 |